IB Middle Years Programme · Biology MYP Year 5

Biotechnology

Cover illustration for Biotechnology (Biology MYP Year 5).
MYP · Biology MYP Year 5

Biotechnology

MYP Year 5 Sciences — Biotechnology unit

24 min readStandardCore MYP Y5 Sciences unit — assessed through Criterion A (Knowing & Understanding) and Criterion D (Reflecting on Impacts of Science); recurring in data-based CRISPR case studies and ethics/evaluation extended-response questions

Biotechnology is where biology stops being purely descriptive and turns into an engineering problem — you're not just learning what cells do, you're learning how humans hijack, edit and rebuild biological systems for medicine, food and industry. Every exam question here hands you a graph, a data table, or a real-world scenario and asks you to reason through it. Reciting a definition of 'CRISPR' or 'cloning' gets you nothing without the mechanism underneath it and the trade-offs sitting on top of it.

Overview — the shape of biotechnology

Biotechnology uses living organisms, cells or their molecules to build something useful — a copy of an organism, a piece of tissue, a corrected gene, or a map of an entire genome. The five ideas in this unit (cloning, bioprinting, genetic modification, ethics, genome mapping) aren't separate topics — they're stages of the same story: read the genome understand it copy/edit/print it decide whether you should have.

  • Cloning and genetic modification both manipulate DNA/cells, but cloning copies without changing the sequence — GM deliberately changes it.
  • 3D bioprinting is the 'manufacturing' end of biotech — turning biological material into a physical structure, layer by layer.
  • Genome mapping is the information layer underneath everything else — you can't edit or clone intelligently without first knowing what the genome contains.
  • Ethics isn't a bolt-on topic in exams — almost every scenario question (pricing, patenting, germline editing) is testing whether you can name a specific stakeholder and consequence, not just say 'it could be misused'.

The shape of the chapter

Command terms this topic loves to use against you

Command termWhat it demandsAOMark-earning move
StateGive a short, precise answer with no explanation needed.Knowledge/recallOne correct fact earns the mark — padding it with explanation wastes time and gains nothing extra.
IdentifyName the specific feature/variable/component being asked for.Knowledge/recallName exactly what's asked (e.g. the precise independent variable) — a vague category answer like 'a variable' scores zero.
ExplainGive the reason or mechanism behind a pattern — the WHY or HOW, not just the WHAT.Understanding/applicationYou need cause linked to effect; describing the trend alone (without the mechanism) caps you below full marks.
CompareState similarities AND differences between two named things.AnalysisLinking words like 'whereas' or 'unlike' score higher than two unlinked separate descriptions.
Discuss / EvaluatePresent multiple viewpoints (benefits AND risks/drawbacks) and weigh them against each other.EvaluationA one-sided answer is capped — top marks need balance, and ideally a final judgement.
SuggestPropose a scientifically reasonable idea, even one not explicitly taught.ApplicationAny biologically plausible answer is accepted — don't leave it blank because it 'wasn't in the notes'.

Key point

Almost every mark lost in this unit is lost the same way: describing a pattern instead of explaining it, or naming a vague ethical worry instead of a specific stakeholder and consequence. Fix that habit first.

Cloning

Cloning produces a genetically identical copy of an existing cell or organism — the DNA sequence itself is not changed, only copied. This is the single most confused idea in the whole unit: cloning is copying, genetic modification is editing.

  • Somatic Cell Nuclear Transfer (SCNT) is the standard technique: the nucleus from a body (somatic) cell of the animal to be cloned is inserted into an egg cell whose own nucleus has been removed (enucleated).
  • An electric shock or chemical stimulus triggers the reconstructed egg to start dividing as if it had been fertilised normally.
  • The resulting embryo is implanted into a surrogate mother and develops into an offspring genetically identical to the original nucleus donor — this is how Dolly the sheep (1996) was produced from a mammary gland cell.
  • Cloning can be reproductive (produces a whole new organism) or therapeutic (produces cells/tissues, usually stem cells, for research or repair — the embryo is never implanted).
Clone
An organism or cell that is genetically identical to another, produced without sexual reproduction.
Somatic Cell Nuclear Transfer (SCNT)
The technique of transferring the nucleus from a body cell into an enucleated egg cell to produce a cloned embryo.
Reproductive cloning
Cloning aimed at producing a complete, living organism genetically identical to the donor.
Therapeutic cloning
Cloning aimed at producing stem cells or tissue for medical research or repair; the embryo is not implanted or allowed to develop into an organism.
Stem cell
An undifferentiated cell capable of dividing and developing into one or more specialised cell types.

Somatic Cell Nuclear Transfer

SCNT: nucleus swapped from a donor body cell into an enucleated egg, then stimulated to divide.

Donor cell (with nucleus)Egg cellRemoval of egg nucleus (enucleation)Nuclear transferElectric/chemical stimulusDividing embryoSurrogate motherCloned offspring

Reproductive vs therapeutic cloning

FeatureReproductive cloningTherapeutic cloning
PurposeProduce a whole new living organismProduce stem cells/tissue for research or repair
Embryo fateImplanted and allowed to develop fullyNever implanted; used to harvest stem cells
ExampleDolly the sheepPatient-specific stem cell lines for disease research
Main ethical concernIdentity, welfare, high failure/abnormality rateDestruction of embryos, source of eggs used

Common mistake

Saying a clone's DNA has been 'changed' or 'edited' to make it identical to the donor.

Consequence: Directly contradicts the definition of cloning — examiners read this as confusing cloning with genetic modification, losing the definition mark outright.

Fix: A clone's DNA sequence is copied, never altered. If the question mentions an edited gene as well as a clone, that's two separate processes (GM + cloning) happening in sequence, not one.

Key takeaways

  • Cloning copies an existing genome; it does not change the DNA sequence.
  • SCNT: donor nucleus → enucleated egg → stimulated division → implantation (reproductive) or stem cell harvest (therapeutic).
  • Reproductive cloning makes a whole organism; therapeutic cloning stops at the cell/tissue stage and is never implanted.

3D tissue and organ printing

3D bioprinting builds living tissue the way a normal 3D printer builds plastic objects — layer by layer — except the 'ink' is a mixture of living cells and a supportive biomaterial.

  • A digital 3D model (often from a patient's own CT/MRI scan) guides the printer head.
  • Bioink — cells suspended in a gel-like biomaterial — is deposited layer by layer to build the structure.
  • A scaffold (often made of biodegradable polymer) supports the shape while cells grow and organise; it breaks down as the tissue matures.
  • The printed structure is matured in a bioreactor, which supplies nutrients and mechanical/chemical cues so cells form functional tissue before implantation.
  • Simple, avascular tissues (skin grafts, cartilage, bladder patches) are furthest along; whole vascularised organs (hearts, kidneys, livers) are still experimental — they need a working blood supply, which is the current bottleneck.
Bioink
A printable material combining living cells with a biocompatible gel/polymer, used as the 'ink' in a 3D bioprinter.
Scaffold
A supportive 3D structure, often biodegradable, that holds printed cells in the correct shape while they grow and organise into tissue.
Biocompatibility
The ability of a material to be used inside or with living tissue without triggering harmful immune rejection or toxicity.

3D bioprinting process

Bioprinting builds tissue layer by layer from a digital model, then matures it in a bioreactor.

Digital 3D model / patient scanBioprinter print headBioink cartridge (cells + biomaterial)Layer-by-layer depositionScaffold structurePrinted tissue constructBioreactor maturation

Where bioprinting actually is right now

Bioprinted skin grafts and cartilage patches are already used in clinical trials and some approved treatments for burns and reconstructive surgery. Fully functional, vascularised organs — a printed kidney or heart that could replace a transplant — are not yet clinically available anywhere; the unsolved problem is printing a working network of tiny blood vessels fast enough to keep thick tissue alive before it's implanted.

Common mistake

Writing that 3D printed organs are 'already used to replace failed organs in hospitals'.

Consequence: Overstates current technology — in an evaluate/discuss question this loses accuracy marks because only simple, thin tissues are in clinical use; full organs remain experimental.

Fix: Separate the claim: 'tissues (skin, cartilage) — some clinical use now' vs 'organs (heart, kidney, liver) — still in research/trial stage, limited mainly by vascularisation'.

Key takeaways

  • Bioprinting = bioink (cells + biomaterial) printed layer by layer onto/around a scaffold, then matured in a bioreactor.
  • Simple tissues (skin, cartilage) are furthest along clinically; whole vascularised organs are still experimental.
  • The main technical barrier for organs is building a functioning blood vessel network fast enough to keep thick printed tissue alive.

Genetic modification

Genetic modification (GM) deliberately changes an organism's DNA sequence — adding, removing or correcting specific genes. CRISPR-Cas9 is the tool that dominates every exam question here because it lets scientists cut DNA at almost any chosen location with three simple components.

  • gRNA (guide RNA) — a short synthetic RNA sequence (~20 nucleotides) complementary to the target DNA. Its complementary base sequence is what lets it recognise the correct site.
  • PAM (Protospacer Adjacent Motif) — a short sequence sitting on the target DNA itself, right next to the region the gRNA matches. Cas9 checks for the PAM FIRST; without a correct PAM next to it, Cas9 will not cut, even if the gRNA sequence matches perfectly elsewhere.
  • Cas9 — the endonuclease enzyme ('molecular scissors'). Once gRNA has base-paired with the target DNA next to a valid PAM, Cas9 cuts both DNA strands, creating a double-strand break (DSB).
  • The cell repairs that break by one of two pathways — Non-Homologous End Joining (NHEJ, direct rejoining, fast and error-prone) or Homology-Directed Repair (HDR, uses a donor template, slower but precise).
Cas9
A bacterial-derived endonuclease that, once guided to the correct site, cuts both strands of the target DNA to create a double-strand break.the molecular scissors
guide RNA (gRNA)
A short synthetic RNA (~20 nt) complementary to the target DNA sequence; its base sequence lets it base-pair with the target and direct Cas9 to that exact genomic location.the GPS for Cas9
PAM (Protospacer Adjacent Motif)
A short sequence on the target DNA, immediately adjacent to the gRNA-matching region, that Cas9 must recognise before it will cut. It is part of the target DNA, NOT part of the gRNA.the permission slip
NHEJ (Non-Homologous End Joining)
The default double-strand-break repair pathway; rejoins the two cut ends directly without a template — fast, but frequently introduces small insertions/deletions (indels).
HDR (Homology-Directed Repair)
A repair pathway that uses a homologous donor DNA sequence as a template to precisely repair the break, allowing a specific, planned edit — slower and less frequent than NHEJ.
GMO (genetically modified organism)
An organism whose genome has been deliberately altered using biotechnology.

CRISPR-Cas9 gene editing mechanism

gRNA base-pairs with target DNA next to the PAM; Cas9 cuts both strands; the cell repairs via NHEJ or HDR.

Cas9 proteinguide RNA (gRNA)PAM sequenceTarget DNADouble-strand breakNHEJ repair pathwayHDR repair pathwayDonor DNA template

Quantities you'll be asked to calculate from CRISPR data tables

The proportion of treated cells that ended up carrying the intended edit.

The proportion of edits that landed somewhere other than the intended target site.

Higher GC content strengthens gRNA-DNA binding but, if too high, raises off-target binding to similar sequences elsewhere in the genome.

Worked example

Explaining the NHEJ vs HDR trend with distance from the cut site

[4]
A graph shows how the frequency of NHEJ and HDR repair changes as the distance from the Cas9 cut site increases from 0 to 100 base pairs: HDR frequency starts high (~70%) at 0 bp and falls to ~10% by 100 bp, while NHEJ frequency starts low (~30%) and rises to ~90%. Explain the trend.

Worked example

Choosing the best gRNA design from efficiency and off-target data

Six gRNAs were tested on the same gene: A (18 nt, 40% GC) → 45% efficiency, 12% off-target; B (20 nt, 50% GC) → 78% efficiency, 5% off-target; C (20 nt, 70% GC) → 82% efficiency, 15% off-target; D (22 nt, 55% GC) → 88% efficiency, 4% off-target; E (24 nt, 60% GC) → 85% efficiency, 6% off-target; F (18 nt, 75% GC) → 50% efficiency, 20% off-target. Identify the best overall gRNA design and justify your choice.

Worked example

Reading repair outcomes from colony sequencing data

A gRNA targeted the sequence 5'-ATCGGCTA-3' in bacteria. Five colonies were sequenced after editing: Colony 1 — perfect repair matching the donor template; Colony 2 — single nucleotide deletion at the cut site; Colony 3 — 2 bp deletion at the cut site; Colony 4 — 1 bp insertion at the cut site; Colony 5 — no change from wild type. For each colony, state which repair pathway (if any) was used, with justification.

Worked example

Identifying variables in a CRISPR antibiotic-resistance experiment

Scientists introduce an antibiotic-resistance gene edit into one group of bacteria using CRISPR-Cas9; a second group receives no edit. Both groups are exposed to the same antibiotic under identical incubation conditions, and survival is recorded. State the independent variable, the dependent variable, and one controlled variable.

'State the function of Cas9' is a 2-mark question with 2 distinct requirements

A one-line answer like 'Cas9 cuts DNA' caps at 1/2. The mark scheme wants: (1) Cas9 is an endonuclease enzyme, AND (2) it creates a double-strand break at a specific site determined by gRNA base-pairing next to a PAM sequence. Missing either half loses a mark.

PAM location confusion

Treating the PAM sequence as part of the gRNA molecule.

Consequence: Wrong component labelled on diagram-based questions (Q6-style), losing the identification mark and undermining the explanation that follows.

Fix: PAM sits on the target DNA itself, immediately adjacent to the region the gRNA matches. Cas9 only cuts when BOTH gRNA-DNA complementarity AND a correct adjacent PAM are present — the PAM check happens before Cas9 even tests the gRNA match.

Pairs that get mixed up under exam pressure

Concept AConcept BThe distinction that matters
NHEJHDRNHEJ directly rejoins the cut ends with no template (fast, error-prone, dominates when the edit site is far from the cut); HDR copies a homologous donor template across the break (slow, precise, only efficient when homology arms sit close to the cut site).
gRNAmRNAgRNA is a synthetic guide sequence that directs Cas9 to a DNA target by base-pairing and is never translated; mRNA carries a protein-coding sequence to ribosomes for translation.
Genetic modification (GM)CloningGM changes the DNA sequence of an organism; cloning produces a genetically identical copy without altering the sequence at all.

Mnemonic

Find, Flag, Fracture

gRNA Finds the complementary target sequence → the PAM Flags it as a genuine, valid target → Cas9 Fractures (cuts) both DNA strands there.

Key takeaways

  • CRISPR-Cas9 needs three things together: gRNA (complementary match), PAM (on the target DNA, checked first), and Cas9 (the endonuclease that cuts).
  • NHEJ = fast, template-free, error-prone (indels); HDR = slow, template-based (donor DNA), precise — and HDR's efficiency drops the further the edit site is from the actual cut.
  • 'Explain the trend' questions always need a mechanism, not a description of the graph shape.
  • Editing efficiency and off-target frequency must be judged together, not separately, when comparing gRNA designs.

Ethical implications

Every biotechnology exam scenario is really asking one question in disguise: who benefits, who is harmed, and who decides? Cloning, bioprinting and gene editing all raise the same recurring categories of concern — you just need to attach them to the specific numbers or details given in the scenario.

  • Access and cost — new therapies (especially gene therapies) are often priced far above what most affected populations can pay, so the people with the greatest need may benefit least.
  • Consent — particularly for germline editing (changes passed to offspring), where future generations cannot consent to changes made to their genome.
  • Patenting and ownership — a company holding exclusive rights to a gene therapy or GM technique can block cheaper generic versions, keeping prices high for years.
  • Safety and unintended effects — off-target CRISPR edits, or unknown long-term effects of GM organisms released into ecosystems.
  • Designer traits — the line between correcting a disease-causing mutation and selecting non-medical traits (appearance, intelligence) is an ongoing societal debate with no settled answer.

Worked example

Identifying distinct societal concerns in a gene-therapy pricing scenario

A biotechnology company patents a CRISPR-Cas9 therapy correcting the HBB gene mutation that causes sickle cell disease, priced at $500,000 per patient. Sickle cell disease affects ~300,000 newborns annually, with over 75% born in sub-Saharan Africa, where average healthcare spending per person is under $100/year. Identify two societal concerns raised by this scenario.

This scenario isn't hypothetical

In late 2023, the FDA and UK's MHRA approved Casgevy, the first CRISPR-based gene therapy, for sickle cell disease — priced at over $2 million per patient in some markets. Sickle cell disease disproportionately affects sub-Saharan Africa, where most patients have no realistic path to accessing it, making the access/patenting debate above a live, current issue rather than an exam invention.

Key point

Every ethics question wants a named, specific stakeholder and a specific consequence tied to the numbers given — 'it could be misused' or 'it's not fair' scores nothing on its own.

Key takeaways

  • The recurring ethical categories are: access/cost, consent (especially germline), patenting/ownership, safety/unintended effects, and designer-trait selection.
  • Two 'concerns' must come from genuinely different categories, not the same point reworded.
  • Always anchor your answer to the specific numbers or details in the scenario — generic ethical statements score zero.

Genome mapping and application

Genome mapping determines the sequence and location of every gene in an organism's genome. The Human Genome Project (completed 2003) sequenced essentially the entire human genome and turned genetics from guesswork into a searchable database — this is the information layer that makes CRISPR targeting, personalised medicine and forensic profiling possible in the first place.

  • Genome sequencing reads the order of bases (A, T, C, G) across an entire genome; bioinformatics is the computational science used to store, search and interpret that enormous amount of data.
  • A single nucleotide polymorphism (SNP) is a common single-base variation between individuals — many SNPs are linked to disease risk or drug response and are the basis of personalised medicine.
  • Genome maps let researchers locate a disease-causing gene (like HBB in sickle cell disease) precisely enough to design a gRNA for CRISPR editing.
  • The same mapping techniques applied to crops and livestock genomes underpin marker-assisted breeding, speeding up selection for drought resistance, yield or disease resistance without needing GM techniques at all.
Genome
The complete set of genetic material (DNA) of an organism.
Genome mapping/sequencing
Determining the order of bases and the location of genes across an entire genome.
Bioinformatics
The use of computational tools to store, organise and analyse large-scale biological data, such as genome sequences.
SNP (Single Nucleotide Polymorphism)
A common variation at a single base position in the genome between individuals, often linked to disease risk or drug response.

Applications of genome mapping

Application fieldExample use of genome dataReal outcome
MedicinePharmacogenomics / disease-risk screeningBRCA1/BRCA2 testing informs breast cancer risk and treatment choices
AgricultureMarker-assisted breeding using crop genome mapsFaster development of drought- and disease-resistant crop varieties
ForensicsDNA profiling/genetic fingerprintingIdentifying suspects or victims from trace biological samples
Evolutionary biologyComparative genomics across species/populationsTracing human migration patterns and evolutionary relationships

Examiner tip

When a question links genome mapping to CRISPR (e.g. 'why is knowing the HBB gene's exact location important?'), the expected answer is that mapping identifies the precise DNA sequence needed to design a matching gRNA — without the map, there's no target to guide Cas9 to.

Key takeaways

  • Genome mapping/sequencing determines the base sequence and gene locations across an entire genome; bioinformatics is the computing science that handles that data.
  • SNPs are single-base differences between individuals, central to personalised medicine.
  • Genome maps are the information foundation for CRISPR targeting, medical diagnostics, agriculture and forensics — mapping comes before editing, not after.

Quick reference

Biotechnology — everything on one page

Formulas

  • Higher = more of the treated population got the intended edit.
  • Lower = safer, more specific gRNA design.
  • Sweet spot ~50-60%: too low weakens binding, too high raises off-target risk.

Key facts

First cloned mammal
Dolly the sheep, 1996 (SCNT)
Human Genome Project completed
2003
First FDA/MHRA-approved CRISPR therapy
Casgevy, sickle cell disease, 2023

Mnemonics

  • Find, Flag, FracturegRNA Finds the target sequence → PAM Flags it as valid → Cas9 Fractures both DNA strands.

Don't confuse

  • Cloning vs Genetic modification: Cloning copies the genome unchanged; GM deliberately alters the DNA sequence.
  • NHEJ vs HDR: NHEJ = fast, template-free, error-prone; HDR = slow, donor-template-based, precise, and distance-sensitive.
  • Reproductive cloning vs Therapeutic cloning: Reproductive cloning produces a whole organism; therapeutic cloning stops at stem cells/tissue, never implanted.

Command terms

Explain:
State the trend AND the mechanism/cause behind it — description alone loses marks.
Identify:
Name the exact feature asked for, not a vague category.
Discuss/Evaluate:
Give both benefits and risks, then weigh them — one-sided answers are capped.

Exam checklist

  • Can I explain WHY a graph trend happens, not just describe its shape?
  • Do I know the three CRISPR components (gRNA, PAM, Cas9) and which molecule each one belongs to?
  • Can I tell NHEJ apart from HDR from sequencing data (indel vs exact donor match)?
  • Can I name two genuinely different ethical concerns, not the same point twice?
  • Do I know what genome mapping is used FOR (medicine, agriculture, forensics) rather than just what it IS?